MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-25-2025
Arrowhead Pharmaceuticals EV/EBITDA Ratio 2011-2026 | ARWR
Annual EV/EBITDA Ratio Arrowhead Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -30.8 | -64.5 | 53.9 | -19.8 | -7.66 | -3.6 | -2.29 | -3.69 | -6.91 | -1.12 | -3.17 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53.9 | -64.5 | -8.15 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
1.8 | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
1.84 | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
ANI Pharmaceuticals
ANIP
|
109 | $ 81.6 | -0.49 % | $ 1.58 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Amgen
AMGN
|
10.7 | $ 342.65 | -0.08 % | $ 184 B | USA |
 |
Adagene
ADAG
|
-4.92 | $ 2.75 | -5.5 % | $ 155 M | China |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
-1.92 | $ 2.63 | 1.74 % | $ 16.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-0.994 | $ 3.17 | -2.76 % | $ 7.63 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
PainReform Ltd.
PRFX
|
-1.36 | $ 0.68 | -4.45 % | $ 308 K |  Israel |
 |
Allena Pharmaceuticals
ALNA
|
0.298 | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
0.957 | - | 1083.1 % | $ 745 M | USA |
 |
Aptose Biosciences
APTO
|
388 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-0.158 | - | -13.39 % | $ 1.45 M | USA |
 |
Biogen
BIIB
|
12.7 | $ 178.24 | 1.2 % | $ 26 B | USA |
 |
Brickell Biotech
BBI
|
0.668 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Molecular Transport
AMTI
|
-1.19 | - | - | $ 10.1 M | USA |
 |
Beam Therapeutics
BEAM
|
-11.7 | $ 27.94 | -4.61 % | $ 2.3 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-15.7 | $ 225.36 | 0.63 % | $ 5 B |  Danmark |
 |
Athira Pharma
ATHA
|
-3.66 | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
-2.76 | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
4.1 | $ 114.18 | -2.22 % | $ 27.2 B | Germany |
 |
CASI Pharmaceuticals
CASI
|
-26.1 | $ 0.99 | -0.01 % | $ 135 M | USA |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Catalyst Biosciences
CBIO
|
0.34 | $ 9.63 | -5.08 % | $ 634 M | USA |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
1.13 | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-12.7 | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
-16.9 | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-43.1 | $ 4.05 | -1.22 % | $ 8.81 B | Israel |
 |
Amneal Pharmaceuticals
AMRX
|
1.63 | $ 13.65 | -3.3 % | $ 4.22 B | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
0.0235 | - | -74.18 % | $ 955 K | USA |
 |
Cerus Corporation
CERS
|
-24.7 | $ 2.32 | -0.22 % | $ 428 M | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-3.39 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-5.5 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-3.61 | - | 4.14 % | $ 49.1 M | USA |